Chairman and Chief Executive Officer
Carrie S. Cox is Chairman and Chief Executive Officer of Humacyte, Inc. She joined Humacyte in 2010. Ms. Cox most recently served as Chairman of Prism Pharmaceuticals, sold to Baxter Corporation in 2011. Ms. Cox was EVP and President, Global Pharmaceuticals, at Schering-Plough Corporation, from 2003 until its merger with Merck & Co., Inc., in November 2009. She was responsible for the company’s global prescription pharmaceutical business, which generated approximately $16 billion in annual sales, with a five year CAGR of 22%. Prior to that, she held a similar role as President, Global Prescription Business at Pharmacia Corporation. Previously, Cox served as SVP of Global Business Management at Pharmacia & Upjohn (the predecessor company to Pharmacia), and as VP of Women’s Healthcare at Wyeth-Ayerst. Cox spent her early career at Sandoz pharmaceuticals (now Novartis) in a variety of commercial roles of increasing responsibility. Cox currently serves on the Boards of Directors of Texas Instruments, Cardinal Health, and Celgene, and she has served as Lead Director for Texas Instruments. Cox has been named six times to FORTUNE Magazine’s list of the “50 Most Powerful Women in Business” and she was named to “Top 10 Women in Biotech” by Fierce Biotech publications in 2012. Her work has been featured in the Harvard Business Review and in the New York Times bestseller, The Profit Zone. She received her B.S. from Massachusetts College of Pharmacy, and worked for several years in retail and hospital pharmacy.
Dr. Niklason is the Nicholas M. Greene Professor at Yale University in Anesthesia and Biomedical Engineering, where she has been on faculty since 2006. Niklason received her PhD in Biophysics from the University of Chicago, and her MD from the University of Michigan. She completed her residency training in anesthesia and intensive care unit medicine at the Massachusetts General Hospital in Boston, and completed post-doctoral scientific training at Massachusetts Institute of Technology.
Dr. Niklason’s research focuses primarily on regenerative strategies for cardiovascular and lung tissues. Niklason’s engineered blood vessels are currently in clinical trials, and are the first life-sustaining engineered tissue to be studied in any Phase III trial. Niklason’s lab was also one of the first to describe the engineering of whole lung tissue that could exchange gas in vivo, and her work was cited in 2010 as one of the top 50 most important inventions of the year by Time Magazine. She was inducted into the National Academy of Inventors in 2014, and was elected to the National Academy of Medicine in 2015.
Dr. Niklason is recognized as a global expert in cellular therapies and regenerative medicine. Today, she continues to teach, maintain a vigorous scientific laboratory, and speaks nationally and internationally on her research and exciting, emerging medical discoveries.
Chief Financial Officer
Mr. Boyer has been a senior executive and entrepreneur at companies such as RivalHealth, Agion Technologies, Solicore, SwitchPoint Networks and BriteSmile. He is highly skilled in start-up, turnaround, high growth and private equity ventures for public and private companies. Mr. Boyer spent the past 25 years as a CFO and/or COO of private and public companies from start-up to $700M in revenues. Prior to Humacyte, Mr. Boyer was Founder and President of FinOps Solutions, Inc., a professional services firm providing CFO/COO services, M&A Advisory and capital raising expertise in public and private markets. During this time, Mr. Boyer was named one of Carolinas’ Best in Business in Forbes Magazine in 2012, and Entrepreneur of the Year by Business Leader Magazine in 2012. He currently serves on the United States Olympic Committee, National Governing Body for Shooting.
Chief Operating Officer
Dr. Lithgow is a psychopharmacologist by training, and most recently President and CSO of Meadwestvaco Corporation Healthcare.
He was formerly senior commercial lead and representative for Schering Plough/Merck global prescription pharmaceutical business, with former responsibility for all cross-Customer divisional initiatives and process at Schering Plough (S-P), and a previous Group Vice-President and General Manager of the Respiratory Joint Venture between the S-P and Merck pharmaceutical organizations. Dr. Lithgow was formerly Vice-President, Commercial Operations and Emerging Technologies at Pharmacia Corporation (Peapack, N.J.).
Dr. Lithgow was a Director of New Products Marketing Global CNS, Psychiatry and Neurology at Wyeth Corporation (Philadelphia, Pa.) and previous Director, U.S. Women’s Health Care Prescription Therapeutics, Contraception and Reproductive Disorders.
Dr. Lithgow is the author of articles in peer reviewed journals, and writes extensively on patient adherence and pharmaceutical packaging.
Chief Medical Officer
Jeffrey H. Lawson, M.D., Ph.D. received his Medical Degree and a Ph.D. in Cell and Molecular Biology from the University of Vermont in Burlington. He then completed a Postdoctoral Fellowship in Biochemistry at the same location and a residency in General and Thoracic Surgery and a Fellowship in Vascular Surgery at Duke University Medical Center in Durham, North Carolina.
Dr. Lawson was formerly Vice Chair, Professor of Surgery and Professor of Pathology at Duke University Medical Center, and also Director of the Vascular Surgery Research Laboratory and Director of Clinical Trials in Vascular Surgery. Dr. Lawson was the Program Director of the General Surgery Research Residency Program and the Medical Director of Department of Surgery Clinical Research Unit.
Dr. Lawson is a physician-scientist, clinically practicing vascular surgery and actively pursuing basic, translational and clinical research. Lawson has had a lifelong interest in the field of blood coagulation and vascular biology and has continuously studied these areas both scientifically and clinically in his laboratory. He has become a recognized leader in the field of vascular translational technology and his Duke-based laboratory has successfully developed a number of molecular, cellular and tissue engineered technologies through translational research studies to first-in-man clinical trials. He is the co-author of over 120 journal articles on the topics of hemostasis, tissue engineering and vascular surgery and lectures on these topics both nationally and internationally. Dr. Lawson’s Duke research laboratory has been funded by grants from the American Heart Association, National Institutes of Health, Department of Defense and various biotechnology companies.
Senior Vice-President - Product Development
Dr. Prichard brings over 15 years of strong scientific, pre-clinical, and clinical leadership experience in the fields of tissue engineering, extracellular matrix biology, and biological response to implantable biomaterials. At Humacyte, Dr. Prichard oversees the development, qualification, and clinical translation of the bioengineered blood vessel platform for hemodialysis. She currently leads the clinical development organization with overall responsibility for vascular research and development, pre-clinical testing, process development for commercial manufacturing, and analysis and quality control testing of manufactured vessels. Dr. Prichard also works closely with our key vascular surgeons and nephrologists to develop their roles as PI’s for Humacyte. Prior to joining Humacyte, she received her Ph.D. from Duke University in Biomedical Engineering with a focus on investigating the healing response to implantable tissue engineered biomaterials. Prior to her doctoral studies, Dr. Prichard completed her Bachelors of Chemical Engineering at the Georgia Institute of Technology and worked as a Research and Development Engineer for Proctor & Gamble.
Co-Founder and Vice-President, Business Operations & Tissue Services
Dr. Blum is a molecular biologist and co-founder of Humacyte. She has spent over 15 years combining her technical expertise with vascular access product development to bring Humacyte’s novel biotechnology platform and potential bioengineered product to market. At Humacyte, Dr. Blum’s work focuses on the development, management, and execution of a scaled manufacturing strategy to support commercial product launch of Humacyte’s acellular vascular vessel. This work includes the business development of key collaborations critical to the success of the organization.
Dr. Blum leads internal and external commercial initiatives with proven skills in alliance management. Her responsibilities include identifying, developing, and managing manufacturing and tissue sourcing collaborations, as well as oversight of all aspects of technology transfer from Humacyte to our manufacturing partners. She works in a matrixed team environment to achieve Humacyte’s goals. Dr. Blum is also responsible for overseeing tissue based regulatory compliance and industry trends in the donation, recovery, processing, and use of human tissue and cells in product manufacturing. She also manages global supply of Humacyte’s investigational product and supports global regulatory initiatives and submissions supporting clinical activities in the US, Europe, and Israel. Dr. Blum received her doctorate in Molecular Biology from Loyola University Chicago with a focus in cardiovascular gene therapy in 2003, and completed her BS at Carthage College in Wisconsin.
Vice-President, Quality, Compliance Management, & Regulatory Affairs
Mr. Tente joined Humacyte in 2008. He has over 24 years of experience in product and bioprocess development for a variety of cell therapy and tissue-engineered products and biologics. He was the Vice President of Operations for Neurotech USA from 2002 to 2007, and helped develop encapsulated cell technology products for the long term delivery of therapeutic occular protein factors to treat chronic diseases of the retina. Previously he was the Director of Operations of Chimeric Therapies, Inc. responsible for manufacturing, quality control and logistics for bone marrow processing and transplantation operations. Previously, he was the Director of Clinical Production at CytoTherapeutics, Inc., responsible for biological process development, manufacturing and quality control for the encapsulated pain cell therapy product. Bill holds Bachelor and Master of Sciences degrees in cell biology and microbiology from the University of Rhode Island and studied at the W. Alton Jones Cell Sciences Center in Lake Placid, NY. He has been a member of the USP Expert Committee on Gene Therapy, Cell Therapy, and Tissue Engineering and is currently the Chairman of this committee.
Dr. Dahl’s leadership experience has spanned technology, product, corporate, and commercial development. She leverages a forward-thinking approach, strong communication skills, and an interest in stakeholder input to define the strategy in emerging biotechnology therapeutics. These strategies focus on bringing complex medical technologies from early research to clinical trials, commercialization, and revenue. Dr. Dahl also focuses on creating and maintaining value around the technology and product brand, and communicating this value in a way that peer professionals and the lay press can understand.
In 2011, the Popular Mechanics Breakthrough Awards named Dr. Dahl a Brilliant Innovator, together with colleagues Laura Niklason and Juliana Blum. Dr. Dahl received a PhD in biomedical engineering from Duke University, and an SB in materials science & engineering from MIT with a focus on biomaterials and medical devices. She has held an adjunct faculty position in surgical research at Duke, and previously performed research in orthopedic surgery at Harvard Medical School.